Prime Medicine Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Prime Medicine, Inc. | ||
| February 28, 2025 | By: | /s/ Keith Gottesdiener |
|---|---|---|
| Keith Gottesdiener | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY AND SIGNATURES
Each person whose individual signature appears below hereby authorizes and appoints Keith Gottesdiener, Allan Reine, and Carman Alenson, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Keith Gottesdiener | President, Chief Executive Officer and Director(Principal Executive Officer) | February 28, 2025 |
| Keith Gottesdiener | ||
| /s/ Allan Reine | Chief Financial Officer(Principal Financial Officer) | February 28, 2025 |
| Allan Reine | ||
| /s/ Carman Alenson | Chief Accounting Officer (Principal Accounting Officer) | February 28, 2025 |
| Carman Alenson | ||
| /s/ Thomas Cahill | Director | February 28, 2025 |
| Thomas Cahill | ||
| /s/ Wendy Chung | Director | February 28, 2025 |
| Wendy Chung | ||
| /s/ Kaye Foster | Director | February 28, 2025 |
| Kaye Foster | ||
| /s/ Michael Kelly | Director | February 28, 2025 |
| Michael Kelly | ||
| /s/ Jeff Marrazzo | Director | February 28, 2025 |
| Jeff Marrazzo | ||
| /s/ Robert Nelsen | Director | February 28, 2025 |
| Robert Nelsen | ||
| /s/ David Schenkein | Director | February 28, 2025 |
| David Schenkein | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss | F-4 |
| Consolidated Statements of Stockholders’ Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.